Europe
The compact NIR backscattering sensor EXspect 271 has an innovative optical measurement system and offers economical and reliable turbidity measurement.
Pharmahungary Group won an SME Instrument Phase I grant with an innovative in-house R&D project, Vezics, www.vezics.com.
BioArctic AB to publish the company’s Full Year Report for the period January – December 2018 on Thursday, February 14, 2019 at 08:00 a.m. CET.
Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG, and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications.
Thomas Wicks, chief strategy officer of New Jersey-based TrialScope, said transparency has picked up over the past few years, particularly as large pharma companies have begun to release information about their own clinical efforts.
In this week’s edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.
The U.S. Food and Drug Administration approved the first treatment for acquired thrombotic thrombocytopenic purpura (aTTP). Sanofi’s Cablivi was given the greenlight and will become a cornerstone of the company’s new rare blood disorders franchise.
Thirteen of those were development programs, the remaining 25 research-stage. In September, the company indicated it was on a cost-cutting program, planning to save 1.5 billion euros this year. Of the programs it is dumping, the most prominent is a mid-phase drug for respiratory syncytial virus (RSV), ALX-0171.
Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment
MagForce introduces practice-oriented, unique, multifaceted application training for the use of NanoTherm Therapy in treating brain tumors
PRESS RELEASES